Adding lenalidomide and nivolumab to the usual drugs for primary CNS lymphoma
Original title: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two added drugs can help treat lymphoma in the brain and spinal cord.
Who this trial is for. This trial is for people with primary central nervous system lymphoma. That is a lymphoma that starts in the brain and spinal cord. The trial tests adding lenalidomide and nivolumab to the usual drugs, rituximab and methotrexate.
Where it stands. This trial has not reported results. The team is looking at how safe the added drugs are, what side effects happen, what dose works best, and how well the drugs work. They also want to see if the study drugs can keep the lymphoma under control longer when given after the first round of chemotherapy. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Doctors do not yet know if this drug combination helps. The study is meant to add to what is known about using lenalidomide and nivolumab for this lymphoma. If this sounds like your situation, you can ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test. It is a way to find out if something works, not care your own doctor can give you. Joining a trial is not a guarantee that you will be helped. Side effects are possible. This is not a promise of a cure.
Source: ClinicalTrials.gov, August 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.